News & Updates

Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.

The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.

In the first 3 months of a newborn’s life, the prevalence of gastroesophageal reflux disease (GERD) is at its peak, but most infants outgrow it by age 1 year, according to a Singapore study, noting that those breastfed at 3 weeks have a lower likelihood of GERD.

The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.

Device-guided breathing (DGB), as facilitated by the RESPeRATE device, appears to reduce test anxiety and can boost subsequent test performance among students, according to a recent study.

The levels of serum levels of LL-37, an antimicrobial peptide whose expression is stimulated by vitamin D, may help assess the risk of disease progression in COVID-19 patients, reports a recent study.